Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer

Revenues down 7% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer

4Q Revenues: $15.1 billion (-7%)

4Q Earnings: $6.3 billion (earnings were $1.4 billion in 4Q11)

YTD Revenues: $59.0 billion (-10%)

YTD Earnings: $14.6 billion (+46%)

Comments: U.S. revenues were $5.8 billion in the quarter, down 9% primarily due to the loss of exclusivity of Lipitor (-79% to $584 million) in November 2011 and Geodon in March 2012. International revenues were $9.3 billion, down 5% due to the losses for Lipitor in Europe in 2Q12 and the unfavorable impact of foreign exchange. Lyrica sales in the quarter were up 13% to $1.1 billion. Prevnar/Prevenar sales were up 19% to $993 million. Celebrex sales were up 12% to $750 million. Viagra sales were up 6% to $553 million. Zyvox sales were up 10% to $349 million. Enbrel sales were up 3% to $957 million. Primary care revenues were down 29% to $3.8 billion. Specialty Care revenues were down 4% to $3.7 billion. Established product sales were up 3% to $2.4 billion. Animal health sales were up 6% to $1.2 billion. Consumer Healthcare sales were up 16% to $936 million. Earnings in the quarter were favorably impacted by the sale of the Nutrition business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters